
Sign up to save your podcasts
Or
You might not be paying attention, or maybe you just hope it goes away. We’re referring to the serious bird flu outbreak that started a bit more than eight months ago. Well, bird flu is still here and the number of reported cases in people is growing. STAT’s infectious disease reporter Helen Branswell joins us for an update. But first, we break down the results from a GLP-1 showdown study that compared Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy. Allison shares her recent reporting on a talent shortage that is posing new challenges to the fast-growing radiopharmaceutical industry.
4.6
300300 ratings
You might not be paying attention, or maybe you just hope it goes away. We’re referring to the serious bird flu outbreak that started a bit more than eight months ago. Well, bird flu is still here and the number of reported cases in people is growing. STAT’s infectious disease reporter Helen Branswell joins us for an update. But first, we break down the results from a GLP-1 showdown study that compared Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy. Allison shares her recent reporting on a talent shortage that is posing new challenges to the fast-growing radiopharmaceutical industry.
1,642 Listeners
4,323 Listeners
111,539 Listeners
469 Listeners
117 Listeners
5,892 Listeners
2,935 Listeners
391 Listeners
60 Listeners
84 Listeners
31 Listeners
141 Listeners
9 Listeners
190 Listeners
42 Listeners